Depressive Disorder, Major, Hepatitis C
Conditions
Keywords
Hepatitis C, Depressive Symptoms
Brief summary
The purpose of this study is develop and test a cognitive-behavioral intervention to prevent depression in methadone maintenance patients receiving medical treatment for hepatitis C.
Detailed description
The purpose of this study is to develop a CBT-D intervention tailored to meet the needs of MMT patients undergoing antiviral treatment for hepatitis C. In the first phase of this project (Year 1), we will develop and pilot the intervention with 20 patients. In the second phase of the project (Years 2 and 3), we will conduct a preliminary, randomized trial with 60 MMT patients to examine the efficacy of the CBT-D intervention relative to standard care condition (SC). We expect that, relative to the SC condition, participants randomized to the CBT-D condition will have decreased likelihood of depression-related antiviral treatment failure, will report lower levels of depressive symptoms, will complete more IFN injections, will have lower HCV RNA levels, and will have fewer illicit drug use days. If the efficacy of this intervention can be established in this trial and in subsequent clinical trials, MMT patients who elect to undergo antiviral therapy will have a valuable adjunct or alternative to the use of antidepressants to prevent depression. If found to be efficacious, this intervention will maximize the receipt of IFN treatment by MMT patients, thereby aiding in the prevention of liver failure, hepatocellular carcinoma, and liver-related death among those with HCV.
Interventions
Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
Sponsors
Study design
Eligibility
Inclusion criteria
* Currently undergoing HCV treatment at RIH * Enrolled in MMT for at least 6 months
Exclusion criteria
* Current major depressive episode * Current suicidality * Currently taking antidepressant medication * Received HCV treatment in past
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| depression-related antiviral treatment failure | 6 months |
Countries
United States